Dyne Therapeutics, Inc. (DYN) analyst actions
Rating and price-target actions on DYN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DYN overview →
5 measured DYN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval | Press release | +3.65% | +8.53% | |
| Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | Press release | +3.80% | +15.85% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc. (DYN) And Encourages Stockholders to Reach Out | Press release | -0.57% | -2.46% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Reach Out | Press release | +0.24% | -0.63% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Dyne Therapeutics, Inc.(DYN) And Encourages Stockholders to Reach Out | Press release | +0.15% | -1.71% |
Keep exploring
More DYN: earnings → · SEC filings → · DYN overview →